990
Participants
Start Date
December 14, 2016
Primary Completion Date
May 26, 2020
Study Completion Date
May 26, 2020
CHF 5993 100/6/12.5 µg
Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
160 µg budesonide + 4.5 µg formoterol fumarate
Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
Chiesi Clinical Trial Site 158001, Keelung
Chiesi Clinical Trial Site 158011, Taipei
Chiesi Clinical Trial Site 158010, Changhua
Chiesi Clinical Trial Site 158010, Changhua
Chiesi Clinical Trial Site 158006, Kaohsiung City
Chiesi Clinical Trial Site 410013, Seoul
Chiesi Clinical Trial Site 410014, Seoul
Chiesi Clinical Trial Site 410002, Goyang-si
Chiesi Clinical Trial Site 158005, Taipei
Chiesi Clinical Trial Site 410012, Bucheon-si
Chiesi Clinical Trial Site 410003, Chuncheon
Chiesi Clinical Trial Site 410005, Jeonju
Chiesi Clinical Trial Site 158003, Douliu
Chiesi Clinical Trial Site 158004, Kaohsiung City
Chiesi clinical Trial Site 156031, Beijing
Chiesi Clinical Trial Site 156026, Beijing
Chiesi clinical Trial Site 156017, Beijing
Chiesi Clinical Trial Site 156012, Beijing
Chiesi Clinical Trial Site 156007, Shenyang
Chiesi clinical Trial Site 156023, Changchun
Chiesi Clinical Trial Site 156036, Changchun
Chiesi clinical Trial Site 156019, Changchun
Chiesi Clinical Trial Site 156014, Shanghai
Chiesi clinical Trial Site 156037, Shanghai
Chiesi Clinical Trial Site 156005, Shanghai
Chiesi Clinical Trial Site 156006, Shanghai
Chiesi Clinical Trial Site 156011, Shanghai
Chiesi clinical Trial Site 156022, Nanjing
Chiesi Clinical Trial Site 156038, Shanghai
Chiesi Clinical Trial Site 156049, Suzhou
Chiesi Clinical Trial Site 156004, Huai'an
Chiesi clinical Trial Site 156034, Tianjin
Chiesi clinical Trial Site 156018, Hangzhou
Chiesi Clinical Trial Site 156046, Linhai
Chiesi clinical Trial Site 156033, Jiangyin
Chiesi Clinical Trial Site 156041, Nanchang
Chiesi clinical Trial Site 156028, Nanchang
Chiesi Clinical Trial Site 156047, Jiujiang
Chiesi Clinical Trial Site 156042, Pingxiang
Chiesi Clinical Trial Site 156002, Fuzhou
Chiesi Clinical Trial Site 156045, Chongqing
Chiesi clinical Trial Site 156032, Chongqing
Chiesi Clinical Trial Site 156040, Changsha
Chiesi Clinical Trial Site 156040, Changsha
Chiesi Clinical Trial Site 156048, Guangzhou
Chiesi Clinical Trial Site 156013, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University site 156001, Guanzhou
Chiesi Clinical Trial Site 156008, Zhanjiang
Chiesi clinical Trial Site 156024, Foshan
Chiesi Clinical Trial site 156003, Nanning
Chiesi clinical Trial Site 156020, Haikou
Chiesi clinical Trial Site 156035, Chengdu
Chiesi Clinical Trial Site 156010, Chengdu
Chiesi clinical Trial Site 156025, Yinchuan
Chiesi Clinical Trial Site 156044, Shijiangzhuang
Chiesi Clinical Trial Site 156043, Baotou
Chiesi Clinical Trial Site 156015, Baotou
Chiesi Clinical Trial Site 156039, Taiyuan
Chiesi Clinical Trial Site 410001, Bucheon-si
Chiesi Clinical Trial Site 410008, Seoul
Chiesi Clinical Trial Site 410007, Seoul
Chiesi Clinical Trial Site 410004, Seoul
Chiesi Clinical Trial Site 410006, Seoul
Chiesi Clinical Trial Site 410009, Gyeonggi-do
Chiesi Clinical Trial Site 410010, Daegu
Chiesi Clinical Trial Site 410011, Seoul
Chiesi Clinical Trial Site 158008, Taichung
Chiesi Farmaceutici S.p.A.
INDUSTRY